ARCHIVES

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Concepts For Education Initiatives In Breast Ca Approved As RFA

July 9, 1993

NCI Phase II Trial Tests Vaccine Plus Hormone Therapy For Recurrent Prostate Cancer

August 26, 2005

Group Urges Journals To Run Corrections For I-ELCAP Papers.

January 25, 2008

US Could Lose Leadership In Research If NIH Budget Is Cut, ASCO President Says

June 2, 1995

ACS Says 41 Percent Survive 5 Years

January 2, 1981

RFAs: Patient Outcomes “5-A-Day” Program

April 10, 1992